FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy.

Abstract

Some cases of nephrotic syndrome in focal and segmental glomerulosclerosis (FSGS) are associated with a circulating factor, the FSGS permeability factor (FSPF). Galactose has a high affinity for FSPF, and experimental data suggest that it could reduce its activity. We describe the case of a 48-year-old male with a nephrotic syndrome found to be resistant to corticosteroids, immunosuppression and plasmaphaeresis. The patient was given oral galactose as a last resort treatment, which was followed by a remission of his nephrotic syndrome that correlated with a reduction of FSPF activity. This case is the first report of a long-standing remission of an FSPF-associated nephrotic syndrome on oral galactose therapy.

• Authors: Eric De Smet, Jean-Philippe Rioux, Hélène Ammann, Clément Déziel, Serge Quérin
• Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 24 Issue 9 Pg. 2938-40 (Sep 2009) ISSN: 1460-2385 [Electronic] England
• PMID: 19509024 (Publication Type: Case Reports, Journal Article)

Chemical References

• Blood Proteins
• Creatinine
• Galactose

Topics

• Administration, Oral
• Blood Proteins (metabolism)
• Creatinine (blood)
• Galactose (administration & dosage, therapeutic use)
• Glomerulosclerosis, Focal Segmental (blood, complications)
• Humans
• Male
• Middle Aged
• Nephrotic Syndrome (blood, drug therapy, etiology)
• Proteinuria (blood, drug therapy, etiology)